Global Veterinary Vaccines Market Outlook, 2029

The Global Veterinary Vaccines market is anticipated to reach USD 11 Billion by 2023, fueled by the increasing focus on animal health and disease prevention.

The global veterinary vaccines market has a rich history rooted in the development of vaccines to combat zoonotic diseases, which affect both animals and humans. This market has grown significantly since the first veterinary vaccines were developed in the late 19th and early 20th centuries, such as the rabies vaccine by Louis Pasteur. The culture of the veterinary vaccines industry is deeply intertwined with public health and agriculture, emphasizing the prevention of disease outbreaks in livestock and pets. This sector has seen extensive research and development to address various infectious diseases in animals, leading to improved animal health and productivity. The competitive landscape of the veterinary vaccines market is characterized by the presence of several key players, including Zoetis, Merck Animal Health, Boehringer Ingelheim, and Elanco Animal Health. These companies focus on innovation and strategic partnerships to maintain their market positions. The market is highly dynamic, with continuous advancements in vaccine technologies, such as recombinant DNA vaccines and vector-based vaccines, driving competition. Companies are also investing heavily in research and development to create new vaccines and improve existing ones, aiming to address the evolving needs of animal health. Government rules and regulations play a crucial role in the veterinary vaccines market. Regulatory bodies such as the U.S. Department of Agriculture (USDA), the European Medicines Agency (EMA), and the World Organisation for Animal Health (OIE) set stringent guidelines for the development, approval, and distribution of veterinary vaccines. These regulations ensure the safety, efficacy, and quality of vaccines, protecting both animal and human health. Compliance with these regulations is essential for market players, as non-compliance can lead to significant financial and reputational consequences. According to the research report, “The Global Veterinary Vaccines Market Outlook, 2029” published by Bonafide Research, the market is anticipated to reach USD 11 Billion in 2023. Several factors influence the growth of the veterinary vaccines market. Increasing awareness about animal health and zoonotic diseases, rising pet ownership, and the growing demand for animal-derived food products are significant drivers. Additionally, the emergence of new and exotic animal diseases, climate change, and globalization of trade are influencing the market dynamics. However, challenges such as high costs of vaccine development, stringent regulatory requirements, and limited access to veterinary services in certain regions can hinder market growth. One special aspect of the veterinary vaccines market is its dual focus on livestock and companion animals. Livestock vaccines are essential for preventing diseases that can devastate agricultural economies, such as foot-and-mouth disease and avian influenza. Companion animal vaccines, on the other hand, are crucial for preventing diseases in pets, such as rabies, distemper, and parvovirus. This dual focus requires companies to develop a diverse range of vaccines to cater to different animal species and disease profiles. Strategies in the veterinary vaccines market often involve mergers and acquisitions, collaborations, and partnerships. These strategies enable companies to expand their product portfolios, enhance their research and development capabilities, and enter new geographic markets. Additionally, companies are increasingly adopting advanced technologies such as genetic engineering and biotechnology to develop innovative vaccines. Market players are also focusing on improving vaccine delivery systems, such as oral and intranasal vaccines, to enhance vaccine administration and compliance.

What's Inside a Bonafide Research`s industry report?

Asia-Pacific dominates the market and is the largest and fastest-growing market in the animal growth promoters industry globally

Download Sample

Market RestraintsStringent Regulatory Requirements: The development and commercialization of veterinary vaccines are subject to stringent regulatory requirements, including safety, efficacy, and quality criteria. Complying with these regulations can be time-consuming and costly, acting as a restraint to market growth. • High R&D Costs: The research and development (R&D) process for veterinary vaccines involves significant investments in pre-clinical and clinical trials, as well as manufacturing infrastructure. The high R&D costs associated with vaccine development can pose challenges to market expansion. Market Trends

Make this report your own

Have queries/questions regarding a report?

Take advantage of intelligence tailored to your business objective

Manmayi Raval

Manmayi Raval

Research Consultant

Increasing Adoption of Companion Animals: The growing trend of pet ownership, particularly in urban areas, is driving the demand for veterinary vaccines. Pet owners are increasingly aware of the importance of preventive healthcare and are seeking vaccination services to protect their pets from infectious diseases. • Shift towards Precision Vaccines: Precision vaccines, tailored to specific pathogens or strains, are gaining traction in the veterinary vaccine market. These vaccines offer enhanced efficacy, reduced adverse effects, and improved immune response compared to traditional broad-spectrum vaccines. Market Drivers Rising Demand for Animal Protein: The increasing global demand for animal protein, driven by population growth, urbanization, and changing dietary preferences, is a major driver for the veterinary vaccine market. Vaccination programs are essential in maintaining the health and productivity of livestock, ensuring a sustainable supply of safe and quality animal protein. • Growing Awareness of Zoonotic Diseases: Zoonotic diseases, transmitted from animals to humans, pose a significant public health threat. The awareness of zoonotic diseases, such as avian influenza, rabies, and brucellosis, has increased the demand for veterinary vaccines as a preventive measure to mitigate the risk of disease transmission. • Government Initiatives and Regulations: Governments and regulatory authorities are implementing initiatives and regulations to control and eradicate animal diseases. These efforts include vaccination campaigns, disease surveillance programs, and mandatory vaccination requirements, which drive the adoption of veterinary vaccines.

Don’t pay for what you don’t need. Save 30%

Customise your report by selecting specific countries or regions

Specify Scope Now
Manmayi Raval

Inactivated vaccines lead the veterinary vaccine industry due to their safety profile and broad applicability across different animal species. In the veterinary vaccine industry, inactivated vaccines hold a prominent position primarily due to their safety and versatility. Unlike live attenuated vaccines, which use weakened forms of pathogens, inactivated vaccines are made from killed pathogens or purified components. This characteristic makes them inherently safer, as there is no risk of the pathogen causing disease in the vaccinated animal. This safety profile is crucial in veterinary medicine, where the health and welfare of animals are paramount concerns. The broad applicability of inactivated vaccines across various animal species further enhances their utility. Veterinary medicine serves a diverse range of animals, including livestock such as cattle, pigs, and poultry, as well as companion animals like dogs, cats, and horses. Inactivated vaccines can be formulated to target specific diseases affecting each species, providing effective protection without the risk of causing disease or complications. This flexibility in formulation allows veterinarians to tailor vaccination protocols to the specific needs and disease challenges faced by different animal populations. Inactivated vaccines are often preferred in situations where there are concerns about the stability of live vaccines or when the pathogen itself is difficult to attenuate for safe use. For instance, some pathogens may not have a suitable attenuated form that retains sufficient immunogenicity while ensuring safety. In such cases, inactivated vaccines offer a viable alternative by using killed pathogens or purified antigens to stimulate an immune response. Another significant advantage of inactivated vaccines is their ability to induce immune responses that are typically strong and specific. While live attenuated vaccines mimic natural infections and can confer broad-spectrum immunity, inactivated vaccines can still elicit robust immune responses, particularly when adjuvants are used to enhance immunogenicity. This capability is critical in controlling and preventing diseases that pose significant threats to animal health and productivity. In veterinary practice, the safety of vaccines is a paramount concern not only for the animals but also for the humans handling them. Inactivated vaccines provide a higher level of safety assurance compared to live vaccines, reducing the potential risks associated with accidental exposure or transmission of the vaccine strain. This safety aspect is particularly important in intensive farming systems where disease outbreaks can have severe economic consequences. Canines are leading in the veterinary vaccine industry due to their widespread domestication, close proximity to humans, and susceptibility to infectious diseases. The dominance of canines in the veterinary vaccine industry stems from a combination of factors intrinsic to their relationship with humans and their susceptibility to various infectious diseases. Dogs have been domesticated for millennia, evolving from their wild ancestors into companions deeply integrated into human societies worldwide. This close proximity to humans exposes them to a variety of pathogens, making vaccination a crucial aspect of their healthcare. Canines, including pet dogs and working dogs such as police or service animals, occupy a unique position among companion animals. Their roles range from family pets to essential workers, each category requiring tailored vaccination strategies. For instance, pet dogs often receive vaccines against core diseases like rabies, distemper, parvovirus, and adenovirus, protecting both the animals and their human counterparts from zoonotic risks. These diseases can be devastating not only to individual animals but also to public health if left unchecked. The sheer number of domesticated dogs globally contributes significantly to the demand for canine vaccines. According to estimates, there are over 470 million pet dogs worldwide, with the number steadily increasing. This large population necessitates extensive vaccination campaigns to prevent outbreaks and maintain herd immunity, particularly in densely populated urban areas where dogs live in close quarters. The veterinary vaccine industry recognizes the economic and social impact of diseases in canines. Preventing outbreaks through effective vaccination programs not only saves lives but also reduces the financial burden on pet owners and veterinary healthcare systems. Vaccinating against diseases like leptospirosis, canine influenza, and bordetella not only protects individual animals but also contributes to public health by reducing the reservoirs of infectious agents that could potentially affect other animals or humans. The advancement of veterinary science has led to the development of innovative vaccine technologies tailored specifically for dogs. These include recombinant vaccines that offer broader protection with fewer side effects, as well as vaccines formulated to be effective in diverse canine populations, considering factors like age, breed, and geographic location. North America leads in the veterinary vaccine industry primarily due to its robust research and development infrastructure, regulatory framework promoting innovation, and a large market driven by high pet ownership rates. North America's pre-eminence in the veterinary vaccine industry can be attributed to several interconnected factors that collectively foster innovation, production, and distribution of veterinary vaccines. At the forefront is the region's advanced research and development (R&D) infrastructure, encompassing top-tier academic institutions, private research centres, and collaborations between academia and industry. These entities collectively drive the discovery and development of new vaccines, leveraging cutting-edge technologies and scientific expertise to address emerging infectious diseases and improve existing vaccine formulations. The regulatory environment in North America also plays a pivotal role in its leadership. Regulatory agencies such as the U.S. Department of Agriculture (USDA) and the Canadian Food Inspection Agency (CFIA) maintain rigorous standards for vaccine efficacy, safety, and quality. This regulatory framework not only ensures the reliability and effectiveness of veterinary vaccines but also stimulates innovation by providing clear pathways for product approval and market entry. The stringent yet transparent regulatory processes instil confidence in consumers and stakeholders, facilitating investment in R&D and commercialization efforts. North America boasts a substantial market for veterinary vaccines driven by high pet ownership rates and the widespread adoption of companion animals as integral parts of households. The region's affinity for pets translates into a robust demand for preventive healthcare products, including vaccines that protect against common infectious diseases like rabies, distemper, parvovirus, and Lyme disease. The willingness of pet owners to invest in their animals' health contributes significantly to the economic viability of veterinary vaccine manufacturers and encourages continuous innovation in vaccine development. Considered in this report • Historic year: 2018 • Base year: 2023 • Estimated year: 2024 • Forecast year: 2029 Aspects covered in this report • Veterinary Vaccine market Outlook with its value and forecast along with its segments • Various drivers and challenges • On-going trends and developments • Top profiled companies • Strategic recommendation By Product • Attenuated Live Vaccines • Conjugate Vaccines • Inactivated Vaccines • Subunit Vaccines • Toxoid Vaccines • DNA Vaccines • Recombinant Vaccines By Species • Companion Animals • Canine • Avian • Feline • Livestock Animals • Aquatic • Bovine • Others(Porcine, Ovine/Caprine, Poultry, Equine) By Disease • Anaplasmosis • Foot & Mouth Disease • New Castle Disease • Distemper Disease • Others (Influenza, Porcine Reproductive & Respiratory Syndrome (PRRS)) The approach of the report: This report consists of a combined approach of primary and secondary research. Initially, secondary research was used to get an understanding of the market and list the companies that are present in it. The secondary research consists of third-party sources such as press releases, annual reports of companies, and government-generated reports and databases. After gathering the data from secondary sources, primary research was conducted by conducting telephone interviews with the leading players about how the market is functioning and then conducting trade calls with dealers and distributors of the market. Post this; we have started making primary calls to consumers by equally segmenting them in regional aspects, tier aspects, age group, and gender. Once we have primary data with us, we can start verifying the details obtained from secondary sources. Intended audience This report can be useful to industry consultants, manufacturers, suppliers, associations, and organizations related to the Veterinary Vaccine industry, government bodies, and other stakeholders to align their market-centric strategies. In addition to marketing and presentations, it will also increase competitive knowledge about the industry.

Request Table of Contents

First Name

Last Name

Company Name

Job Title

Business Email

Contact Number


Global Veterinary Vaccines Market Outlook, 2029

Contact usWe are friendly and approachable, give us a call.